TheraRadar
Data updated: Jun 28, 2026

NEMBUTAL SODIUM (pentobarbital sodium) · EPIC PHARMA LLC

CNS Approved 1973-09-19

Parenteral Sedatives. Hypnotics, for the short-term treatment of insomnia, since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks (See " Clinical Pharmacology " section). Preanesthetics. Anticonvulsant, in anesthetic doses, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics.

Source: FDA Label
4
Indications
--
Phase 3 Trials
52
Years on Market

Details

Status
Discontinued
First Approved
1973-09-19
Routes
ORAL, INJECTION
Dosage Forms
CAPSULE, INJECTABLE

Companies

Active Ingredient: PENTOBARBITAL SODIUM

NEMBUTAL SODIUM Approval History

1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
23 FDA actions from 1973 to 2019
Feb 2019 SUPPL
Label · Labeling
Apr 2017 SUPPL
Label · Labeling
May 2007 SUPPL
Label · Labeling

What NEMBUTAL SODIUM Treats

7 indications

NEMBUTAL SODIUM is approved for 7 conditions since its original approval in 1973. These indications span multiple therapeutic areas including oncology, immunology, and more.

Source: FDA Label

NEMBUTAL SODIUM Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to NEMBUTAL SODIUM

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

PFIZERPEN
PENICILLIN G POTASSIUM
2 shared
Pfizer
Shared indications:
MeningitisTetanus
AMBIEN
ZOLPIDEM TARTRATE
1 shared
COSETTE
Shared indications:
AMBIEN CR
ZOLPIDEM TARTRATE
1 shared
COSETTE
Shared indications:
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

NEMBUTAL SODIUM FDA Label Details

Indications & Usage

Parenteral Sedatives. Hypnotics, for the short-term treatment of insomnia, since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks (See " Clinical Pharmacology " section). Preanesthetics. Anticonvulsant, in anesthetic doses, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics.

Track NEMBUTAL SODIUM with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.